About Us

BioAdaptives, Inc., (OTCBB: BDPT) was incorporated in Delaware during 2013; our shares have traded publicly in the Over-the-Counter market since 2014, and we are an SEC-reporting issuer. Bioadaptives is primarily a marketing company; we investigate, develop and sell natural botanical and algal products, including dietary supplements and specialty food items, for humans and animals under licenses from several companies. Our preparations are mainly based on Traditional Chinese Medicine and Ayurvedic principles and rely on natural compounds that demonstrate anti-viral, anti-inflammatory and antioxidant properties.

Since 2014, BioAdaptives® has been engaged in advanced investigations on primitive cells, including stem cells and their derivatives, and natural blue-green algae formulations that promote activation of these cells. Primitive cells are important not only for cellular repair from injury and illness but also as a central feature of immune defense against viruses and other microbials. PrimiLungs™, PrimiCell® and PluriPain® are safe and highly effective natural supplements developed with Bioadaptives’ research. In addition to these products, the Company offers the Lung Cleanser™, an advanced, FDA cleared device, to support both lung health and better breathing. Further, the newest product to be developed is MORO2™, a super-oxygenated water made with patented technology, designed to optimize performance, endurance and stamina.

All of our plant-based products have significant anti-viral, anti-inflammatory and antioxidant properties, and are drug-free. Our products are designed to aid in breathing, pain relief, immune defense, cognition, focus, fatigue reduction, sleep, healing, improved overall emotional and physical wellness, and anti-aging. Continuing wellness research includes innovative natural nootropic and sleep formulations, as well as, sports performance enhancement.

During our investigations, we also found our products provided numerous benefits for animals, including performance horses and companion pets. September 2019, in response to rising consumer demand, we launched a new Division, Livestock Impact, with its own website and marketing program. The purpose is to introduce a full line of natural, effective and cost-friendly wellness supplements to complement livestock nutrition programs and to educate owners on achieving a simple, successful path to the winners’ circle. In addition, Livestock Impact, will also offer a wellness and anti-aging line for companion pets. 



Dr. Edward E. Jacobs, Jr., a graduate of Princeton University and Harvard Medical school, is a biotechnology consultant with over 25 years’ experience in biopharmaceutical and medical device development, as well as, 35 years of teaching and direct patient care. Dr. Jacobs has participated in drug development process from discovery through animal and human studies, including regulatory support for FDA and international regulatory affairs, strategic planning and investor relations.

Dr. Jacobs has extensive clinical operations experience, having executed more than 15 human trials in the US, Europe, Eastern Europe, and the Republic of South Africa. He has also served as a medical monitor and liaison for clinical investigators involved with international trials with responsibility for regulatory compliance.

After completing surgical training at Harvard and research positions at the National Heart, Lung and Blood Institute, Bethesda, Maryland, and at Saint Thomas’ Hospital Medical School, London, Dr. Jacobs was a member of the Harvard Medical School staff, combining teaching with clinical practice and research. He has also served on the Scientific Advisory Board of the Armenise-Harvard Foundation and the Publications Committee for the New England Journal of Medicine Scientifically, Dr. Jacobs has made original observations in the field of tissue oxygenation therapy and water modification. His current focus is on natural products for animal and human use, anti-ageing strategy, and primitive cell biology.

He is an author of more than 40 scientific publications and is the holder of four patents.



Robert Ellis brings more than forty years of business management experience to the Company.  He has worked extensively in senior positions across a variety of industry disciplines, including aerospace, electronics, communications, and international marketing.  Mr. Ellis has been an executive officer in private and public companies, both major entities, start-ups, and emerging entities.  He has an Accounting Degree from the University of Illinois, and is a CPA.



Press Releases

SEC Edgar and OTC Filings 

Notice to Investors

Open drop down